Biotech investors often chase early-stage companies in the hope that a single breakthrough trial will deliver massive returns ...

GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape ...

While the fears about the impact of AI pummel software stocks, many leading industrial and biotech companies are seeing huge ...

This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, ...

The US MFN healthcare policy aims to cap US prescription drug prices at the lowest price paid in other developed countries.

The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...

Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings ...

The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics and the ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

US biotech Gilead Sciences today announced that its Trodelvy (sacituzumab govitecan-hziy) has now been added to the National ...